140 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Acquired by Coastline Trust Co

Coastline Trust Co bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the third quarter, HoldingsChannel reports. The institutional investor bought 140 shares of the company’s stock, valued at approximately $71,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Crewe Advisors LLC bought a new stake in IDEXX Laboratories in the first quarter valued at about $26,000. Ridgewood Investments LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at approximately $27,000. Institutional & Family Asset Management LLC bought a new position in IDEXX Laboratories during the second quarter worth $28,000. E Fund Management Hong Kong Co. Ltd. boosted its holdings in IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC increased its stake in IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock valued at $34,000 after purchasing an additional 60 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Barclays reduced their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Piper Sandler reaffirmed a “neutral” rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. BTIG Research assumed coverage on IDEXX Laboratories in a report on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target on the stock. Finally, JPMorgan Chase & Co. lowered their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $552.38.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $420.91 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $404.74 and a 12-month high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The firm has a market capitalization of $34.47 billion, a price-to-earnings ratio of 40.59, a price-to-earnings-growth ratio of 3.75 and a beta of 1.36. The business has a 50 day simple moving average of $468.32 and a 200 day simple moving average of $482.73.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. During the same period in the previous year, the firm earned $2.53 EPS. IDEXX Laboratories’s revenue was up 6.6% on a year-over-year basis. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.